139 related articles for article (PubMed ID: 29025990)
1.
Baum RP; Singh A; Schuchardt C; Kulkarni HR; Klette I; Wiessalla S; Osterkamp F; Reineke U; Smerling C
J Nucl Med; 2018 May; 59(5):809-814. PubMed ID: 29025990
[TBL] [Abstract][Full Text] [Related]
2. Proof of Therapeutic Efficacy of a
Schulz J; Rohracker M; Stiebler M; Goldschmidt J; Stöber F; Noriega M; Pethe A; Lukas M; Osterkamp F; Reineke U; Höhne A; Smerling C; Amthauer H
J Nucl Med; 2017 Jun; 58(6):936-941. PubMed ID: 28254866
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma.
Yin X; Wang M; Wang H; Deng H; He T; Tan Y; Zhu Z; Wu Z; Hu S; Li Z
Amino Acids; 2017 Aug; 49(8):1325-1335. PubMed ID: 28536844
[TBL] [Abstract][Full Text] [Related]
4. Comparative Evaluation of the Biodistribution Profiles of a Series of Nonpeptidic Neurotensin Receptor-1 Antagonists Reveals a Promising Candidate for Theranostic Applications.
Schulz J; Rohracker M; Stiebler M; Goldschmidt J; Grosser OS; Osterkamp F; Pethe A; Reineke U; Smerling C; Amthauer H
J Nucl Med; 2016 Jul; 57(7):1120-3. PubMed ID: 26940767
[TBL] [Abstract][Full Text] [Related]
5. Development of [
Wang M; Zhang H; Wang H; Feng H; Deng H; Wu Z; Lu H; Li Z
Mol Pharm; 2018 Aug; 15(8):3093-3100. PubMed ID: 29889537
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeled neurotensin analog, 99mTc-NT-XI, evaluated in ductal pancreatic adenocarcinoma patients.
Buchegger F; Bonvin F; Kosinski M; Schaffland AO; Prior J; Reubi JC; Bläuenstein P; Tourwé D; García Garayoa E; Bischof Delaloye A
J Nucl Med; 2003 Oct; 44(10):1649-54. PubMed ID: 14530481
[TBL] [Abstract][Full Text] [Related]
7. Dose response of pancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy using 177Lu-DOTATATE.
Ilan E; Sandström M; Wassberg C; Sundin A; Garske-Román U; Eriksson B; Granberg D; Lubberink M
J Nucl Med; 2015 Feb; 56(2):177-82. PubMed ID: 25593115
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of DOTA-chelated neurotensin analogs with spacer-enhanced biological performance for neurotensin-receptor-1-positive tumor targeting.
Jia Y; Shi W; Zhou Z; Wagh NK; Fan W; Brusnahan SK; Garrison JC
Nucl Med Biol; 2015 Nov; 42(11):816-23. PubMed ID: 26302836
[TBL] [Abstract][Full Text] [Related]
9. Systemic Radioligand Therapy with (177)Lu Labeled Prostate Specific Membrane Antigen Ligand for Imaging and Therapy in Patients with Metastatic Castration Resistant Prostate Cancer.
Heck MM; Retz M; D'Alessandria C; Rauscher I; Scheidhauer K; Maurer T; Storz E; Janssen F; Schottelius M; Wester HJ; Gschwend JE; Schwaiger M; Tauber R; Eiber M
J Urol; 2016 Aug; 196(2):382-91. PubMed ID: 26964917
[TBL] [Abstract][Full Text] [Related]
10. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
[TBL] [Abstract][Full Text] [Related]
11. Investigation of the Biological Impact of Charge Distribution on a NTR1-Targeted Peptide.
Jia Y; Zhang W; Fan W; Brusnahan S; Garrison J
Bioconjug Chem; 2016 Nov; 27(11):2658-2668. PubMed ID: 27661393
[TBL] [Abstract][Full Text] [Related]
12. Pancreatic cancer bears overexpression of neurotensin and neurotensin receptor subtype-1 and SR 48692 counteracts neurotensin induced cell proliferation in human pancreatic ductal carcinoma cell line PANC-1.
Wang JG; Li NN; Li HN; Cui L; Wang P
Neuropeptides; 2011 Apr; 45(2):151-6. PubMed ID: 21272935
[TBL] [Abstract][Full Text] [Related]
13. Biomarkers for subtypes of pancreatic ductal adenocarcinoma.
Venkatesan P
Lancet Oncol; 2017 Dec; 18(12):e718. PubMed ID: 29129444
[No Abstract] [Full Text] [Related]
14. Supportive care in pancreatic ductal adenocarcinoma.
Laquente B; Calsina-Berna A; Carmona-Bayonas A; Jiménez-Fonseca P; Peiró I; Carrato A
Clin Transl Oncol; 2017 Nov; 19(11):1293-1302. PubMed ID: 28612201
[TBL] [Abstract][Full Text] [Related]
15. Treatment of Pancreatic Adenocarcinoma in Elderly Patients over 75 Years of Age: A Retrospective Series of 129 Patients.
Oziel-Taieb S; Faure M; Gilabert M; Autret A; Turrini O; Moureau-Zabotto L; Giovannini M; Rousseau F; Raoul JL
J Gastrointest Cancer; 2016 Mar; 47(1):15-9. PubMed ID: 26545612
[TBL] [Abstract][Full Text] [Related]
16. Effect of calculation method on kidney dosimetry in
Heikkonen J; Mäenpää H; Hippeläinen E; Reijonen V; Tenhunen M
Acta Oncol; 2016; 55(9-10):1069-1076. PubMed ID: 27219529
[TBL] [Abstract][Full Text] [Related]
17. Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma.
Stillebroer AB; Boerman OC; Desar IM; Boers-Sonderen MJ; van Herpen CM; Langenhuijsen JF; Smith-Jones PM; Oosterwijk E; Oyen WJ; Mulders PF
Eur Urol; 2013 Sep; 64(3):478-85. PubMed ID: 22980441
[TBL] [Abstract][Full Text] [Related]
18. CT Texture Analysis of Ductal Adenocarcinoma Downstaged After Chemotherapy.
Ciaravino V; Cardobi N; DE Robertis R; Capelli P; Melisi D; Simionato F; Marchegiani G; Salvia R; D'Onofrio M
Anticancer Res; 2018 Aug; 38(8):4889-4895. PubMed ID: 30061265
[TBL] [Abstract][Full Text] [Related]
19. Locally advanced anaplastic pancreatic adenocarcinoma with initial response to FOLFIRINOX and rapid progression after five months.
Shinagare AB; Ramaiya NH; Bellizzi AM; Mayer RJ
Pancreatology; 2012; 12(1):35-8. PubMed ID: 22487471
[TBL] [Abstract][Full Text] [Related]
20. Stabilised 111In-labelled DTPA- and DOTA-conjugated neurotensin analogues for imaging and therapy of exocrine pancreatic cancer.
de Visser M; Janssen PJ; Srinivasan A; Reubi JC; Waser B; Erion JL; Schmidt MA; Krenning EP; de Jong M
Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1134-9. PubMed ID: 12768332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]